FDA Approves Expanded Age Indication for Arexvy RSV Vaccine
The expanded indication is for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in adults aged 50 through 59 years who are at an increased risk.
Stay updated with breaking news from Increased Risk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The expanded indication is for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in adults aged 50 through 59 years who are at an increased risk.
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1 Clinical development programme continues to...
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1 Clinical development program continues to evaluate safety and immunogenicity...
NEWS RELEASE CUC Addresses Generation Capacity and Increased Risk of Load-Shedding Amidst Rising Energy Demand in Grand Cayman Grand...